5-bromo-2'-deoxyuridine | 85395-67-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5-bromo-2'-deoxyuridine
• 英文别名: 3'-deoxy-5-bromouridine；1-(3-deoxy-β-D-erythropentofuranosyl)-5-bromouracil；5-Bromo-3'-deoxyuridine；5-bromo-1-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 85395-67-1
• 化学式: C₉H₁₁BrN₂O₅
• 分子量: 307.101
• InChiKey: SQIFTTCATAHMLW-CVTKMRTPSA-N

物化性质

• 密度：
  1.905±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  三甲基氯硅烷 、 5-bromo-2'-deoxyuridine 在 吡啶 、 六甲基二硅氮烷 作用下， 反应 2.0h， 以98%的产率得到5-bromo-2'-deoxy-3',5'-(diOTMS)uridine
  参考文献：
  名称：

  Synthèe, caractérisation et propriétés cytotoxiques des premiers ‘métallocénonucléosides’

  摘要：

  The synthesis of the first 'metallocenonucleosides' (nucleosides containing a metallocenic moiety in their framework) of the formula Ns-C = C-Fc, Ns-CH = CH-Fc and Ns-CH2-CH2-Fc (Ns = uridine, deoxyuridine, adenosine; Fc: C5H4FeC5H5) has been conducted in the presence of palladium salt according to the following routes: i) reaction of a 5-chloromercuri-nucleoside on ethynylferrocene; ii) hydrozirconation (Schwartz' reagent) of ethynylferrocene followed by the reaction of a 5-halogeno nucleoside; iii) direct coupling between ethynylferrocene and a 5-halogeno nucleoside. The same procedures allowed the synthesis of the corresponding 'metallocenonucleobases' Nb-C = C-Fc, Nb-CH = CH-Fc and NbCH2CH2Fc (Nb = uracil, cytosine, adenine) which have also been prepared by acid solvolysis of the nucleosides precursors. The compounds obtained were purified by HPLC technique and were characterized by H-1 NMR and mass spectrometry. The cytotoxicity in vitro has been studied on L 1210 cells. Only modest activity has been observed.

  DOI：

  10.1016/0223-5234(91)90070-4
• 作为产物：
  描述：

  尿嘧啶核苷 在 吡啶 、 4-二甲氨基吡啶 、 偶氮二异丁腈 、 四丁基氟化铵 、 溴 、 三正丁基氢锡 、 silver nitrate 、 溶剂黄146 作用下， 以 四氢呋喃 、 四氯化碳 、 甲苯 、 乙腈 为溶剂， 反应 147.0h， 生成 5-bromo-2'-deoxyuridine
  参考文献：
  名称：

  各种3'-脱氧嘧啶核苷类似物的合成和抗癌活性以及1-（3-脱氧-β-D-苏-戊呋喃糖基）胞嘧啶的晶体结构。

  摘要：

  已经合成了多种3'-脱氧嘧啶核苷类似物，以评估其作为潜在的抗癌和抗病毒剂。在这些化合物中，1-（3-脱氧-β-D-苏-戊呋喃糖基）胞嘧啶（10，3'-脱氧-ara-C）和3'-脱氧胞苷（22）对CCRF-CEM具有显着的抗癌活性，L1210 ，P388和S-180癌细胞系在体外产生的3'-deoxy-ara-C ED50值分别为2、10、5和34 microM（10）；对于3'-脱氧胞苷（22），分别为25、5、2.5和15 microM。因此，对于CCRF-CEM细胞，3'-脱氧-ara-C（10）的活性是3'-脱氧胞苷（22）的12.5倍。证明了3'-脱氧-ara-C（10）的2'-O-乙酰基，5'-O-乙酰基和2'，5'-二-O-乙酰基衍生物，化合物34、31和30抗癌活性与3'相同 -针对CCRF-CEM，L1210，P388和S-180细胞的-deoxy-ara-C（10）。5'

  DOI：

  10.1021/jm00106a034

文献信息

• Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
  申请人：——

  公开号：US20030087873A1

  公开（公告）日：2003-05-08

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  该公开的发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖有关的病况的组合物和方法，适用于宿主，包括动物，尤其是人类，使用通用式（I）-（XXIII）的核苷或其药学上可接受的盐或前药。该发明还提供了一种有效的过程，用于量化病毒载量，特别是BVDV、HCV或西尼罗河病毒载量，使用实时聚合酶链反应（RT-PCR）。此外，该发明揭示了可以与样本中存在的病毒数量成比例发光的探针分子。
• Method for the treatment or prevention of flavivirus infections using nucleoside analogues
  申请人：——

  公开号：US20020019363A1

  公开（公告）日：2002-02-14

  The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.

  本发明涉及一种使用核苷类似物在宿主体内治疗或预防黄病毒感染的方法，包括给予具有公式I或其药学上可接受的盐的治疗有效量的化合物。
• Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation
  申请人：Stuyver Lieven

  公开号：US20110269707A1

  公开（公告）日：2011-11-03

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  本公开发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖相关的条件的组合物和方法，适用于宿主，包括动物，特别是人类，使用通式（I）-（XXIII）的核苷或其药学上可接受的盐或前药。本发明还提供了一种有效的过程，用于定量病毒载量，特别是BVDV、HCV或西尼罗河病毒载量，在宿主中使用实时聚合酶链反应（“RT-PCR”）。此外，本发明还揭示了探针分子，可以与样品中存在的病毒数量成比例地发出荧光。
• MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
  申请人：GILEAD SCIENCES, INC.

  公开号：US20140057863A1

  公开（公告）日：2014-02-27

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  本公开发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感病毒）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖相关的条件的组合物和方法，适用于宿主，包括动物，特别是人类，使用一种核苷酸的一般式（I）-（XXIII）或其药学上可接受的盐或前药。本发明还提供了一种有效的过程，用于定量病毒载量，特别是BVDV、HCV或West Nile病毒载量，在宿主中使用实时聚合酶链反应（“RT-PCR”）。此外，本发明还揭示了可以与样品中存在的病毒数量成比例发光的探针分子。
• LIN, TAI-SHUN;YANG, JING-HUA;LIU, MAO-CHIN;SHEN, ZHI-YI;CHENG, YUNG-CHI;P+, J. MED. CHEM., 34,(1991) N, C. 693-701
  作者：LIN, TAI-SHUN、YANG, JING-HUA、LIU, MAO-CHIN、SHEN, ZHI-YI、CHENG, YUNG-CHI、P+

  DOI：——

  日期：——